Business Standard

Glenmark Pharma hits four-year high, surges 10% in two days

The company has entered into an agreement with Forest Labs to develop novel mPGES-1 inhibitors to treat chronic inflammatory conditions, including pain.

SI Reporter  |  Mumbai 

Glenmark Pharmaceuticals has rallied over 5% to Rs 547, its highest level since September 2008, with heavy volumes on the NSE. The stock opened at Rs 522 and has seen a combined 1.28 million shares changing hands on the counter so far compared to less than one million shares that were traded daily in past two weeks.

The stock has outperformed the market by surging 10% in past two trading sessions compared to 1% rise in benchmark Sensex after the company informed the stock exchanges that it has entered into an agreement with (Forest Labs) to develop novel mPGES-1 inhibitors to treat chronic inflammatory conditions, including pain.

Under the terms of agreement, Forest Labs will make a $6-million up-front payment and provide an additional $3 million to support the next phase of work. Forest Labs will make other future payments in FY2014 to support the ongoing mPGES-1 inhibitors programme.

Analyst at Sharekhan recommended a BUY on the stock with the revised target price of Rs 600 saying that it an important development for the company having positive repercussions in the long term.

RECOMMENDED FOR YOU

Glenmark Pharma hits four-year high, surges 10% in two days

The company has entered into an agreement with Forest Labs to develop novel mPGES-1 inhibitors to treat chronic inflammatory conditions, including pain.

Glenmark Pharmaceuticals has rallied over 5% to Rs 547, its highest level since September 2008, with heavy volumes on the NSE. The stock opened at Rs 522 and has seen a combined 1.28 million shares changing hands on the counter so far compared to less than one million shares that were traded daily in past two weeks.

Glenmark Pharmaceuticals has rallied over 5% to Rs 547, its highest level since September 2008, with heavy volumes on the NSE. The stock opened at Rs 522 and has seen a combined 1.28 million shares changing hands on the counter so far compared to less than one million shares that were traded daily in past two weeks.

The stock has outperformed the market by surging 10% in past two trading sessions compared to 1% rise in benchmark Sensex after the company informed the stock exchanges that it has entered into an agreement with (Forest Labs) to develop novel mPGES-1 inhibitors to treat chronic inflammatory conditions, including pain.

Under the terms of agreement, Forest Labs will make a $6-million up-front payment and provide an additional $3 million to support the next phase of work. Forest Labs will make other future payments in FY2014 to support the ongoing mPGES-1 inhibitors programme.

Analyst at Sharekhan recommended a BUY on the stock with the revised target price of Rs 600 saying that it an important development for the company having positive repercussions in the long term.

image

LIVE MARKET

BSE 26392.38

161.19 (0.61 %)

NSE 8001.95

53.00 (0.67%)

Widgets Magazine

STOCK WATCH

Company Price() Chg(%)
Future Consumer 16.15 11.76
Kolte Patil Dev. 164.95 10.30
Vakrangee 118.45 9.88
PC Jeweller 384.50 9.34
Gateway Distr. 361.20 7.32
> More on BSE Gainers
Company Price() Chg(%)
Future Consumer 16.25 12.07
Kolte Patil Dev. 166.00 11.00
Vakrangee 118.35 9.89
L G Balakrishnan 491.15 8.78
Gateway Distr. 363.50 8.33
> More on NSE Gainers
Company Price() Chg(%)
Sunrise Asian 260.70 -9.98
Symphony 2083.30 -6.39
I O B 34.95 -5.41
Indbull.RealEst. 62.55 -5.01
Goldline Intl. 205.50 -4.99
> More on BSE Gainers
Company Price() Chg(%)
Rasoya Proteins 0.20 -20.00
Usha Martin 15.25 -5.86
I O B 35.35 -5.73
GHCL 115.70 -5.47
Gammon India 13.90 -5.12
> More on NSE Gainers
Widgets Magazine
Widgets Magazine
Widgets Magazine

Derivatives

Index
Instrument Type
Expiry Date
Option Type
Strike Price